Long-term immune response to SARS-CoV-2 infection among children and adults after mild infection

July 14, 2022
Study provided insights into the long-term features of the immune response to COVID-19 for different age classes, which could help in future COVID-19 vaccination strategies and prevention policies.

A study published in JAMA Network Open of Italian children and adults with SARS-CoV-2 infection, found that anti–SARS-CoV-2 S-RBD IgG persisted until 12 months after infection in all age groups, with significant higher antibody peaks for younger individuals at every follow-up point. This study may provide an important basis to determine the schedule of COVID-19 vaccination in non–previously infected children and of booster immunization in pediatric patients who have already experienced COVID-19.

In this cohort study, researchers evaluated the dynamic changes of the SARS-CoV-2 binding antibody titers in 252 family clusters mostly affected by asymptomatic or mild COVID-19 up to 12 months after initial infection. The findings suggest that anti–SARS-CoV-2 S-RBD IgG may persist more than a year from infection in all age groups, with antibody titers that inversely correlate with age.

Read the full study here

More on COVID